Testosterone Cypionate (Azmiro) - Notification
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and prior authorization notification criteria for Azmiro (testosterone cypionate IM) administered by a healthcare professional for testosterone replacement and select indications; applies to Blue Cross NC membership.
Requirement for use of a self-administered formulation of testosterone unless certain criteria are met.
Requirement for trial and failure of testosterone cypionate (Depo-Testosterone).
Requirement that the patient will not be treated for age-related or late-onset hypogonadism.
Added maximum units and Site of Care medical necessity criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.